Zydus Lifesciences Q4 FY26 profit up 9%, buyback

Earnings snapshot: profit rises despite exceptional costs

Zydus Lifesciences reported an 8.7% year-on-year rise in consolidated net profit for Q4 FY26 at ₹1,272.5 crore, supported by growth across India, international markets, and consumer wellness. Revenue from operations increased 16% year-on-year to ₹7,587 crore. The company also reported profit before exceptional item and tax (PBT) of ₹2,057.2 crore in the quarter, up 8.75% year-on-year.

A key detail in the quarter was an exceptional item of ₹397.5 crore, primarily linked to a one-time expenditure related to the Mirabegron litigation settlement. Even with this one-off, operating performance remained firm, with EBITDA rising 20.2% year-on-year to ₹2,554.4 crore. EBITDA margin improved to 33.7% from 32.6% in Q4 FY25.

What the board approved: buyback and dividend

Alongside the results, the board approved a ₹1,100 crore buyback and a 100% dividend, as referenced in the results coverage. The combination of higher earnings, margin improvement, and capital return decisions became the main immediate talking point for investors tracking Zydus Lifesciences during market hours.

Segment performance: India, international and consumer wellness lead

Zydus Lifesciences reported broad-based segment growth in Q4 FY26. India formulations revenue rose 14% year-on-year to ₹1,752.8 crore and contributed 24% to consolidated revenue. The company also noted that its branded business grew 15% year-on-year, faster than the market.

International markets formulations revenue increased 45% year-on-year to ₹804 crore, driven by demand across emerging markets and Europe. Consumer wellness posted the sharpest growth, with revenue up 61% year-on-year to ₹1,463.3 crore, aided by performance in skin and hair care brands and international operations. MedTech revenue was reported at ₹327.5 crore during the quarter.

Consumer wellness details: mixed domestic trends, strong categories

Within consumer wellness, the company disclosed contrasting trends in the domestic business and product categories. Domestic business grew 1.7% year-on-year in Q4 FY26. Seasonal brands declined 9.8% year-on-year, while skin and hair care brands grew 39.7% and food and nutrition brands rose 9.4% year-on-year.

These category-level numbers matter because the consumer wellness business was a meaningful driver of consolidated growth in the quarter, and the mix indicates that non-seasonal categories carried momentum even as seasonal brands softened.

Key financial metrics table

Segment revenue table (Q4 FY26)

Full-year FY26: profit and revenue growth stays steady

For FY26, Zydus Lifesciences reported consolidated net profit of ₹5,040 crore, up 11.37% from ₹4,525.5 crore in FY25. Revenue from operations for FY26 increased 16.81% to ₹27,148.4 crore, compared with ₹23,241.5 crore in FY25. The company also reported that, for the full year, net profit increased 11% and revenue grew 17%.

Stock reaction: shares end higher after results

The results were announced during market hours, and the stock moved higher on the day. Zydus Lifesciences gained 2.80% to close at ₹1,018.95 following the Q4 FY26 announcement.

How Q4 compared with earlier expectations and recent quarters

Separately, pre-result commentary in the provided text showed analyst expectations for Q4 FY26 revenue in the ₹5,400-5,800 crore range and PAT in the ₹950-1,050 crore band, with EBITDA margin projections of 28-30%. Reported Q4 FY26 revenue of ₹7,587 crore and net profit of ₹1,272.5 crore were above those cited estimate ranges.

The dataset also includes Q3 FY26 numbers for context: revenue from operations of ₹6,864.5 crore (up 30.3% year-on-year) and net profit of ₹1,042.1 crore. It also notes sequential trends in Q3 FY26, including revenue rising 12.1% quarter-on-quarter from ₹6,123.2 crore in Q2 FY26, while net profit declined from ₹1,258.6 crore due to higher exceptional expenses.

Market impact and what to track next

For investors, the immediate market takeaway was that Zydus delivered double-digit revenue growth and improved margins even after factoring in a significant one-time exceptional expense in Q4 FY26. Segment disclosures point to strong growth in international markets formulations and consumer wellness, while India formulations continued to contribute a sizeable portion of consolidated revenue.

Attention is likely to remain on the execution in consumer wellness categories, the sustainability of international markets momentum, and how capital allocation evolves after the approved ₹1,100 crore buyback and the 100% dividend decision.

Conclusion

Zydus Lifesciences closed Q4 FY26 with net profit of ₹1,272.5 crore on revenue of ₹7,587 crore, supported by strong segment growth and margin improvement, even as it absorbed a ₹397.5 crore exceptional item. The board’s buyback approval adds a second headline alongside earnings, while FY26 numbers show continued expansion in profit and revenue.